Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jul. 01, 2012
Operating activities:
Net income	$ 60,141	$ 56,202
Add: net income from discontinued operations and dispositions, net of income taxes	(916)	(558)
Net income from continuing operations	59,225	55,644
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and lease charges, net	22,587	11,362
Depreciation and amortization	62,810	64,163
Stock-based compensation	7,642	10,252
Amortization of deferred debt issuance costs	1,680	1,745
Amortization of acquired inventory revaluation	203	4,774
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	14,630	13,473
Inventories, net	(17,550)	(12,652)
Accounts payable	3,478	1,645
Accrued expenses and other	(115,978)	(56,594)
Excess tax benefit from exercise of equity grants	0	(1,139)
Net cash provided by operating activities of continuing operations	38,727	92,673
Net cash (used in) provided by operating activities of discontinued operations	66	(744)
Net cash provided by operating activities	38,793	91,929
Investing activities:
Capital expenditures	(22,852)	(11,449)
Proceeds from Life Insurance Policies	220	0
Changes in restricted cash balances	0	(200)
Payments for acquisitions and investments, net of cash and cash equivalents acquired	(49)	0
Net cash used in investing activities of continuing operations	(22,681)	(11,249)
Net cash provided by investing activities of discontinued operations	494	988
Net cash used in investing activities	(22,187)	(10,261)
Financing activities:
Payments on debt	(282,000)	(244,000)
Proceeds from borrowings	340,000	210,000
Payments of debt issuance costs	0	(416)
Payments for (Proceeds from) Hedge, Financing Activities	1,363	0
Payments on other credit facilities	5,264	0
Payments for acquisition-related contingent consideration	0	(9,343)
Excess tax benefit from exercise of equity grants	0	1,139
Proceeds from stock options exercised	7,289	11,746
Purchases of common stock	(126,993)	(2,063)
Dividends paid	(15,892)	(15,891)
Net cash (used in) provided by financing activities	(70,969)	(48,828)
Effect of exchange rate changes on cash and cash equivalents	(4,611)	(3,779)
Net (decrease) increase in cash and cash equivalents	(58,974)	29,061
Cash and cash equivalents at beginning of period	171,444	142,342
Cash and cash equivalents at end of period	$ 112,470	$ 171,403